What Does The Future Hold For Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266)? These Analysts Have Been Cutting Their Estimates

Today is shaping up negative for Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266) shareholders, with the analysts delivering a substantial negative revision to this year's forecasts. This report focused on revenue estimates, and it looks as though the consensus view of the business has become substantially more conservative.

After the downgrade, the three analysts covering Suzhou Zelgen BiopharmaceuticalsLtd are now predicting revenues of CN¥750m in 2024. If met, this would reflect a sizeable 94% improvement in sales compared to the last 12 months. The loss per share is anticipated to greatly reduce in the near future, narrowing 74% to CN¥0.26. Yet before this consensus update, the analysts had been forecasting revenues of CN¥957m and losses of CN¥0.26 per share in 2024. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a serious cut to their revenue forecasts while also making no real change to the loss per share numbers.

Check out our latest analysis for Suzhou Zelgen BiopharmaceuticalsLtd

Of course, another way to look at these forecasts is to place them into context against the industry itself. The analysts are definitely expecting Suzhou Zelgen BiopharmaceuticalsLtd's growth to accelerate, with the forecast 94% annualised growth to the end of 2024 ranking favourably alongside historical growth of 49% per annum over the past three years. Compare this with other companies in the same industry, which are forecast to grow their revenue 23% annually. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Suzhou Zelgen BiopharmaceuticalsLtd to grow faster than the wider industry.

The Bottom Line

While analysts did downgrade their revenue estimates, these forecasts still imply revenues will perform better than the wider market. Often, one downgrade can set off a daisy-chain of cuts, especially if an industry is in decline. So we wouldn't be surprised if the market became a lot more cautious on Suzhou Zelgen BiopharmaceuticalsLtd after today.

Still, the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Suzhou Zelgen BiopharmaceuticalsLtd going out to 2026, and you can see them free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.